Latest Intelligence on Cardiovascular and Diabetes in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

UK health: childhood obesity epidemic feared

A government report published this week reveals that childhood obesity in the UK has tripled in the last 20 years and calls for urgent steps to be taken. The committee is right to advocate the establishment of a high level government committee to tackle obesity, annual BMI tests for children, and a ban on junk food advertising in a bid to address the issue.

Published By Datamonitor
28 May 2004
Expert View
Expert View

UK doctors slow to utilize combination therapy for hypertension

According to new Datamonitor research, the majority of hypertension sufferers are not fully controlled on a single antihypertensive therapy. With many patients requiring a combination of two or three drugs from different classes to adequately lower their blood pressure, not enough doctors are recognizing the importance of multiple drug administration.

Published By Datamonitor
26 Nov 2004
CommentWire
CommentWire

UK cardiovascular disease: statins for all?

Researchers have suggested that in order to tackle heart disease in the country, nearly all middle-aged UK men should receive statins as preventative medicine. This claim points to the great need for new guidelines concerning statin use. However, new guidelines alone might not be enough to combat the prevalence and high cost of cardiovascular disease as more effective measures are required.

Published By Datamonitor
26 May 2006
Expert View
Expert View

Type 2 diabetes driving epidemic

Type 2 diabetes poses one of the greatest public health threats of the 21st century. As well as increasing the potential patient population, type 2 diabetes has also raised the profile of the disease. However, a new Datamonitor report estimates that while 55 million people are affected by type 2 diabetes, only 50% of patients are diagnosed, and only 80% of those actually receive treatment.

Published By Datamonitor
21 Feb 2008
ResearchWire
ResearchWire

Stroke: two-fifths of UK emergency testing takes more than two hours

Published By Datamonitor
26 Jun 2001
ResearchWire
ResearchWire

Stroke: only 3% of Japanese cases occur in hospitals

Published By Datamonitor
23 Jul 2001
ResearchWire
ResearchWire

Stroke: 7% of UK patients present within necessary time window

Published By Datamonitor
09 Jul 2001
CommentWire
CommentWire

Stents: new findings could dramatically change the market

A study has suggested that the mortality risk posed by stent thrombosis is increased five-fold for STEMI patients receiving drug-eluting stents, compared to bare-metal stents. If proven, stent development is likely to move away from new drug-coated stents allowing smaller companies a chance to compete with leading players such as Boston Scientific and Johnson & Johnson.

Published By Datamonitor
06 Sep 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.